PTGX
Protagonist Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$134.27-4.71%
Price as of Jul 20, 2026
PTGX profitability
Protagonist Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 99.5%
- EBITDA margin
- -153.8%
- EBIT margin
- -192.4%
- Net margin
- -154.9%
- Free cash flow margin
- -157.0%
Returns
- Return on equity
- -17.5%
- Return on assets
- -16.4%
- Return on invested capital
- -21.4%
- Asset turnover
- 0.11x
Cash efficiency
- Cash from operations
- -$116.6M
- Cash per share
- $8.52
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.